How Does This Work?
JPM-MCS, and other customers (DTRA/JSTO, etc.), offers funding opportunities to MCDC members through solicitations called Requests for Prototype Proposals (RPPs). The RPPs offer MCDC members the opportunity to propose prototype technologies to the technology requirements in each solicitation’s sub-objective area. Active and Forecasted solicitations are listed below, as are the status of RPPs for which submissions have been received.
If you are not a MCDC member and wish to become one, please click here for instructions.
| RPP Release # (Date) | Requirements | Requiring Office | Submission Type | Submission Due Date |
|---|---|---|---|---|
| RPP-22-13 (07/28/2022) | MCDC2213: Development of Relevant Animal Models to Support Medical Countermeasure (MCM) Development against Traditional and Emerging Bio-Threats | DTRA RD-CBM | Enhanced White Paper | 08/22/2022 Noon Eastern |
| RPP-22-14 (08/08/2022) | MCDC2214: Layered Medical Defense against Biological Threats | DTRA RD-CBM | Enhanced White Paper | 09/06/2022 Noon Eastern |
| RPP-22-12 (07/11/2022) | MCDC2212: Non-Clinical and Early Clinical Development of 3,4-Diaminopyridine Phosphate (3,4-DAPP) for Treatment of Botulinum Neurotoxin (BoNT) Intoxication | DTRA RD-CBM | Enhanced White Paper | 09/06/2022 Noon Eastern |
| RPP-22-15 (08/11/2022) | MCDC2215: Small Molecules or Biologics as Host Targeted or Host Disease Process Targeted, Broad-Spectrum Medical Countermeasures (MCM) against Biological Threats of Concern | DTRA RD-CBM | Enhanced White Paper | 09/08/2022 Noon Eastern |
| Estimated Q2FY22 | MEDFIND-MED3D: AI-Assisted Optimization of Combination Drug Treatment Regimens | DTRA RD-CBM | ||
| Estimated Q3FY22 | mAb and Animal Model Development for Intoxication by Marine Toxins | DTRA RD-CBM | ||
| Estimated Q3FY22 | Development of Therapeutics with Broad Spectrum Activity against Organophosphate Nerve Agents | DTRA RD-CBS | ||
| Estimated Q2FY22 | Alphavirus models and alternative endpoints | DTRA RD-CBM |
Received: # of proposals received
Selected: # of proposals selected for award at time of Selection Announcement Letter
Basket: # of proposals placed in basket
*Proposal pulled from basket for award
*Awarded: Full Executed Project Agreements (Prime Awardee Listed Only)
*In Evaluation: Government is performing Source Selection
*In Negotiation: Government has made selections and Offerors have been notified. SOW development and negotiations are on-going.
| RPP Release # (Date) | Requirement | Requiring Office | Submission Status | Awardee | Award Date | Estimated Value |
|---|---|---|---|---|---|---|
| RPP-22-11 (05/16/2022) | 22-11: Therapeutic Medical Countermeasure Strategies for Addressing Emerging Bacterial Threats | DTRA-RD-CBM | Received: Selected: Basket: | In Evaluation | ||
| RPP-22-10 (04/29/2022) | 22-10: ReVAMP: ReinVigorating Abandoned AntiMicrobial Products | DTRA RD-CBM | Received: Selected: Basket: | In Evaluation | ||
| RPP-22-09 (03/09/2022) | 22-09: Multivalent Vaccine Prototype for Encephalitic Alphaviruses | DTRA-RD-CBM | Received: Selected: Basket: | In Evaluation | ||
| RPP-22-08 (03/03/2022) | 22-08: Reconstitution Auto Injector Platform | JPM-CBRN Medical | Received: 8 Selected: 2 Basket: | In Negotiation | ||
| RPP-22-07 (01/19/2022) | 22-07: Needle-Free Vaccine Delivery Platform Prototypes | DTRA-RD-CBM | Received: Selected: Basket: | In Evaluation | ||
| RPP-22-06 (01/12/2022) | 22-06: Vaccine Encapsulation Prototype | DTRA-RD-CBM | Received: Selected: Basket: | In Evaluation | ||
| RPP-22-05 (01/05/2022) | 22-05: Adjuvant Activity to Vaccines Prototype | JSTO and DTRA | Received: Selected: Basket: | In Evaluation | ||
| RPP-22-04 (11/10/2021) | 22-04: mRNA Vaccines to Prevent Biological Threat Agent Diseases | JPEO-CBRND Medical | Received: 12 Selected: 5 Basket: 5 | In Negotiation | ||
| RPP-22-03 (11/17/2021) | 22-03: Accelerated Antibodies (mAb) Prototype Development | JPEO-CBRND-EB | Received: 10 Selected: 2 Basket: 2 | Mapp Biopharmaceuticals | 06/24/2022 | $59,966,758 |
| RPP-22-02 (10/05/2021) | 22-02: High Throughput Screening (HITS) Prototype | DTRA-CBM | Received: 5 Selected: 2 Basket: 1 | In Negotiation | ||
| RPP-22-01 (10/01/2021) | 22-01: Pathogenesis and Toxicity Forecasting Using Multi-Organoid Systems (PATMOS) | DTRA-CBM | Received: 4 Selected: 1 Basket: 1 | Wake Forest University | 04/27/2022 | $36,600,000 |
| RPP-21-06 (08/23/2021) | 21-06: Dry Neutralizing Unbroken Skin Decontaminant Technologies | DTRA | Received: 12 Selected: 2 Basket: 3 | Clear Scientific LLC Guild Associates, Inc. | 05/09/2022 05/10/2022 | $6,500,000 $2,814,293 |
| RPP-21-05 (04/06/2021) | 21-05: Breath-Based Bacterial and Viral Diagnostic (B3VID) | DTRA-RD-CBA | Received: 6 Selected: 2 Basket: 1 | Indiana University | 09/10/2021 | $1,297,494 |
| RPP-21-04 (3/22/2021) | 21-04: Novel Broad Spectrum Antibacterial Medical Countermeasures (MCM) for Treatment and Post-Exposure Prophylaxis (PEP) of Melioidosis | DTRA/JSTO | Received: 4 Selected: 1 Basket: 1 | Arrevus, Inc. | 08/25/2021 | $45,494,165 |
| RPP-21-03 (01/22/2021) | 21-03: Novel Biologics as Medical Countermeasures (MCM) against Biological Threats of Concern | DTRA/JSTO | Received: 16 Selected: 2 Basket: 6 | University of Pittsburgh | 03/17/2022 | $14,515,945 |
| RPP-21-02 (12/10/2020) | 21-02: Small Molecules as Medical Countermeasures (MCM) against Biological Threats of Concern | DTRA/JSTO | Received: 7 Selected: 2 Basket: 2 | Southwest Research Institute Latham BioPharm Group | 09/10/2021 09/29/2021 | $24,983,966 $14,209,447 |
| RPP-21-01 (11/10/2020) | 21-01: Development of Relevant Animal Models to Support Medical Countermeasure (MCM) Development against Bio-Threats | DTRA/JSTO | Received: 6 Selected: 2 Basket: 2 | The University of Texas Medical Branch at Galveston Texas Biomedical Research Institute | 07/31/2021 09/28/2021 | $10,544,459 $14,209,447 |
| RPP-20-17 (9/18/2020) | 20-17: COVID-19 Pandemic – Vaccine Manufacturing Scale Up | BARDA/JPM-CBRN Medical | Received: 8 Selected: 0 Basket: 4 | No Awards Made | ||
| RPP-20-16 (9/03/2020) | 20-16: Point of Need Diagnostic Platform | DTRA-RD-CBA | Received: 8 Selected: 1 Basket: 0 | Darwin Biosciences, Inc. | 06/09/2021 | $7,741,187 |
| RPP-20-15 (8/26/2020) | 20-15: Clinical Trials of Repurposed Drugs for COVID-19 Therapeutic | DTRA-RD-CBM | Received: 4 Selected: 1 Basket: 0 | Leidos | 12/23/2020 | $70,162,055 |
| RPP-20-14 (08/20/2020) | 20-14: Immune Modulator Platform Clinical Trials for COVID-19 | HHS/ASPR/BARDA | Received: 2 Selected: 2 Basket: 0 | Quantum Leap Healthcare Collaborative | 12/2/2020 | $66,549,901 |
| RPP-20-13 (8/04/2020) | 20-13: Adaptive Platform Clinical Trials for COVID-19 | DTRA-RD-CBM | Received: 4 Selected: 1 Basket: 0 | Quantum Leap Healthcare Collaborative | 11/19/2020 | $5,631,751 |
| RPP-20-12 (7/23/2020) | 20-12: Phase 1 Clinical Dose Escalation Study of rVSVΔG SARS-CoV-2 Vaccine | DTRA-RD-CBM | Received: Selected: Basket: | In Evaluation | ||
| RPP-20-11 (6/9/2020) | 20-11: COVID-19 Pandemic Vaccine Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing | BARDA/JPM-CBRN-Medical | Received: 11 Selected: 4 Basket: 2 | Novavax, Inc. Pfizer Sanofi Janssen Research & Development | 7/06/2020 7/21/2020 7/31/2020 8/05/2020 | $1,600,434,522 $2,002,500,000 $1,769,013,740 $1,001,650,000 |
| RPP-20-10 (5/29/2020) | 20-10: Universal Blood Sample Preparation Platform to Provide Timely Pre-Symptomatic Diagnosis of Bacterial Infections | DTRA-RD-CBA | Received: 2 Selected: 1 Basket: 0 | General Electric | 12/18/2020 | $5,556,135 |
| RPP-20-09 (5/27/2020) | 20-09: Development of Naloxone Multi-10 mg Dose Use Vial | DTRA RD-CBS | Received: 4 Selected: 1 Basket: 1 | SRI International | 9/10/2021 | $14,689,426 |
| RPP-20-08 (5/17/2020) | 20-08: Support Vaccine Rapid Advanced Research and Development (ARD) to Large Scale Manufacturing | BARDA | Received: 4 Selected: 1 Basket: 1 | Regeneron Pharmaceuticals | 7/06/2020 | $450,262,000 |
| RPP-20-07 (5/06/2020) | 20-07: Development of Diagnostic Tests for the Rapid and Accurate Diagnosis of Human SARS-CoV-2 | DTRA RD-CBA | Received: 10 Selected: 1 Basket: 2 | New Horizons Diagnostics | 5/28/2020 | $2,909,759 |
| RPP-20-06 (05/04/2020) | 20-06: Therapies and Prophylaxes to Treat Coronavirus Disease (2019 (COVID-19)) | JPM-CBRN-Medical | Received: 15 Selected: 3 Basket: 5 | Partner Therapeutics The Ultran Group University of Louisville *Pulmotech | 7/14/2020 9/18/2020 12/02/2020 1/15/2021 | $34,977,402 $1,023,776 $8,547,848 $6,000,000 |
| RPP-20-05 (4/14/2020) | 20-05: Development of EIDD-2801 and Supplemental Candidates | DTRA-RD-CBM | Received: 3 Selected: 2 Basket: 0 | Emory University | 7/9/2020 | $11,192,009 |
| RPP-20-04 (3/19/2020) | 20-04: Advance Treatment Based on Polyclonal Antibodies to Treat Coronavirus Disease 2019 (COVID-19) Response | DoD/DHHS via JPEO-CBRND | Received: 9 Selected: 1 Basket: 0 | Grifols Shared Services North America, Inc. | 4/9/2020 | $12,332,250 |
| RPP-20-03 (1/28/2020) | 20-03: INATS - Soman Nerve Agent Pre-Treatment Pyridostigmine Bromide (SNAPP) Shelf-life Modernization | JPM-CBRN-Medical | Received: 4 Selected: 1 Basket: 2 | CMC Pharmaceuticals, Inc. | 8/24/2020 | $2,118,906 |
| RPP-20-02 (11/20/2019) | 20-02: TRE: INATS - Centrally Acting Medical Countermeasure for Nerve Agent Exposure | JPM CBRN Medical | Received: 7 Selected: 1 Basket: 3 | Battelle Memorial Institute | 8/31/2020 | $38,948,547 |
| RPP-20-01 (11/8/2019) | 20-01: TRE: Small Molecule Antiviral Therapeutic Medical Countermeasures | JPEO-CBRND | Received: 8 Selected: 4 Basket: 1 | Battelle Memorial Institute Evrys Bio | 1/27/2021 06/30/2021 | $11,891,814 $2,796,299 |
| RPP-19-12 (9/10/2019) | 19-12: Phase 1 Clinical Dose Escalation Study of BoNT mAb G03-52-01 DP | JPM CBRN Medical | Received: 1 Selected: 1 Basket: 0 | Ology Bioservices, Inc. | 5/22/2020 | $39,759,022 |
| RPP-19-11 (7/3/2019) | 19-11: Therapeutic Evaluation of 3,4-Diaminopyridine (3,4-DAP) | JPM CBRN Medical | Received: 3 Selected: 1 Basket: 1 | Battelle Memorial Institute | 6/26/20 | $2,882,846 |
| RPP-19-10 (4/30/2019) | 19-10: Development of a Scopolamine Auto Injector Prototype | JPM CBRN Medical | Received: 5 Selected: 1 Basket: 3 | Aktivax | 2/21/2020 | $24,466,039 |
| RPP-19-09 (3/26/2019) | 19-09: In Vitro Affinity-based Diagnostic System for Diseases Resulting from Chemical, Biological, and Radiological Exposure (IADS) | JPM CBRN Medical | Received: 9 Selected: 2 Basket: 2 | University of North Carolina *Duke University | 10/23/2019 3/30/2020 | $13,888,458 $10,736,110 |
| RPP-19-08 (3/1/2019) | 19-08: Medical Countermeasure Prototype Development to Biological Toxins (PRE) | DTRA | Received: 3 Selected: Basket: 2 | *ZabBio | 3/5/2020 | $1,919,469 |
| RPP-19-07 (1/31/2019) | 19-07: Natural Product Chemical Medical Countermeasures | JPM CBRN Medical | Received: 1 Selected: 0 Basket: 0 | No Awards Made | ||
| RPP-19-06 (1/31/2019) | 19-06: Novel and Innovative Prophylaxis/Pretreatment Medical Countermeasures (MCMs) to Protect the U.S. Warfighter Against Adverse Effects of Organophosphorus Nerve Agents (OPNAs) | JPM CBRN Medical | Received: 5 Selected: 1 Basket: 1 | *MRI Global | 6/26/2020 | $19,670,891 |
| RPP-19-05 (1/31/2019) | 19-05 (TRE): Prophylactic and Therapeutic cMCM Libraries, Mid to Late Pipeline Development | JPM CBRN Medical | Received: 6 Selected: 1 Basket: 3 | *Alchem Laboratories MRI Global *MRI Global | 11/21/2019 12/03/2019 12/23/2019 | $13,365,323 $14,548,813 $12,472,695 |
| RPP-19-04 (12/19/2018) | 19-04 (PRE): Ebola Vaccine Prototype | JPM CBRN Medical | Received: 1 Selected: 1 Basket: 0 | The Albert B. Sabin Vaccine Institute | 9/12/2019 | $8,558,226 |
| RPP-19-03 (11/1/2018) | 19-04 (TRE): Development of Naloxone Auto-injector | JPM CBRN Medical | Received: 6 Selected: 1 Basket: 2 | Kaleo, Inc. | 7/29/2019 | $18,807,098 |
| RPP-19-03 (11/1/2018) | 19-03 (TRE): Development of Diazepam Auto-injector | JPM CBRN Medical | Received: 6 Selected: 1 Basket: 3 | Emergent BioSolutions | 9/17/2019 | $21,309,825 |
| RPP-19-02 (12/4/2018) | 19-02 (TRE/PRE): Development and Testing of a Rapid Response Antibody (Ab) Platform System and the Accelerated Development of a Safe and Efficacious Prototype Medical Countermeasure (MCM) Against a Biodefense Threat of Interest | JPM CBRN Medical | Received: 6 Selected: 2 Basket: 3 | SAB Biotherapeutics Inc. Ology | 8/7/2019 8/30/2019 | $129,569,410 $3,716,066 |
| RPP-19-01 (11/20/2018) | 19-01 (TRE): Development of an FDA-Approved Smallpox Medical Countermeasure for a Post-Exposure Prophylaxis Indication | JPM CBRN Medical | Received: 1 Selected: 1 Basket: 0 | SIGA Technologies | 7/2/2019 | $25,839,218 |
| RPP-18-09 (8/8/2018) | 18-22 (PRE): Walter Reed Army Institute of Research Viral Disease Branch (WRAIR, VDB), Good Manufacturing Practices (GMP) Development of Dengue Purified Inactivated Vaccines | JPM CBRN Medical | Received: Selected: Basket: | Requirement Canceled | ||
| RPP-18-06 (3/23/2018) | 18-17 (PRE): Marburg Virus Vaccine Development | DTRA JSTO | Received: 3 Selected: 1 Basket: 2 | *International AIDS Vaccine Initiative | 10/15/2019 | $35,751,818 |
| RPP-18-06 (3/23/2018) | 18-16 (TRE): Novel Therapeutics for Multidrug Resistant Bacterial Bio threat Pathogens | DTRA JSTO | Received: 5 Selected: 1 Basket: 2 | Battelle *University of Florida | 3/1/2019 3/24/2021 | $14,988,991 $36,841,555 |
| RPP-18-05 (4/12/2018) | 18-19 (PRE): Development and utilization a monoclonal antibody platform prototype for development of monoclonal antibodies as medical countermeasures against threats of interest. Aerosolized Plague infection is the subject of this requirement. | JPM CBRN Medical | Received: 2 Selected: 1 Basket: 0 | Ology Bioservices | 3/22/2019 | $148,615,932 |
| RPP-18-04 (4/5/2018) | 18-15 (DET): Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the Plague | DTRA JSTO | Received: 3 Selected: 2 Basket: 0 | Inbios International Brimrose Technology Corp | 8/27/18 9/24/2018 | $4,436,864 $1,675,664 |
| RPP-18-04 (4/5/2018) | 18-14 (PRE): Next Generation Devices for Delivery of Nucleic Acid Vaccines | DTRA JTSO | Received: 4 Selected: 2 Basket: 4 | *Inovio Pharmaceuticals *PharmaJet | 6/6/2019 6/17/2019 | $8,149,588 $9,730,249 |
| RPP-18-04 (4/5/2018) | 18-13 (PRE): Prophylaxis / Pretreatment Against Francisella tularensis | DTRA JTSO | Received: 4 Selected: 1 Basket: 2 | *University of New Mexico *Southwest Research Institute Ology | 9/26/2019 11/5/2019 9/21/2020 | $7,549,230 $18,287,542 $6,315,788 |
| RPP-18-04 (4/5/2018) | 18-12 (PRE): Francisella tularensis Immune Assays | DTRA JTSO | Received: 3 Selected: 0 Basket: 3 | In Negotiation | ||
| RPP-18-04 (4/5/2018) | 18-11 (PRE): Burkholderia Species Immune Assays | DTRA JTSO | Received: 5 Selected: 0 Basket: 4 | *University of Nevada, Reno | 9/12/2019 | $2,505,186 |
| RPP-18-04 (4/5/2018) | 18-10 (DET): Assay Development for the Identification of Markers of Venezuelan Equine Encephalitis Virus Infection in Animal Models | DTRA JTSO | Received: 2 Selected: 1 Basket: 1 | Meso Scale Diagnostics | 4/30/2019 | $2,709,021 |
| RPP-18-04 (4/5/2018) | 18-09 (DET): Multiplex Vertical flow Paper-based Immunoassay (VPI) Diagnostic System | DTRA JTSO | Received: 2 Selected: 0 Basket: 1 | *University of Arizona | 4/6/2020 | $5,414,034 |
| RPP-18-03 (2/9/2018) | 18-08 (TRE): Proof of Concept Formulations for CBRN Medical Countermeasures to be administered via Autoinjector | DTRA JTSO | Received: 5 Selected: 2 Basket: 2 | SRI International Emergent BioSolutions *Southwest Research Institute | 3/4/2019 3/4/2019 6/15/2020 | $5,723,503 $2,236,389 $4,100,812 |
| RPP-18-03 (2/9/2018) | 18-07 (TRE): Discovery and Development of New Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents | DTRA JSTO | Received: 1 Selected: 1 Basket: 0 | Southwest Research Institute | 3/18/2019 | $10,090,377 |
| RPP-18-03 (2/9/2018) | 18-06 (PRE): Enhanced circulatory stability and GMP manufacturing of phosphotriesterase (PTE) / organophosphorous hydrolase (OPH) variants as prophylaxis against a broad-spectrum of organophosphorus nerve agents (OPNAs) | DTRA JSTO | Received: 1 Selected: 1 Basket: 0 | BioHybrid | 6/20/2019 | $38,360,918 |
| RPP-18-02 (1/10/2018) | 18-05 (TRE): Development of a Food and Drug Administration (FDA)-approved medical countermeasure (MCM) for treatment of multi-drug resistant bacterial biological warfare agents delivered via an aerosol route of exposure | JPM CBRN Medical | Received: 1 Selected: 0 Basket: 1 | No Award Made at This Time | ||
| RPP-18-02 (1/10/2018) | 18-04 (TRE): Relevant Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic Evaluations | JPM CBRN Medical | Received: 2 Selected: 1 Basket: 1 | SciTech Services | 9/12/2018 | $235,797 |
| RPP-18-01 (10/19/2017) | 18-03 (TRE): Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents | DTRA JSTO | Received: 1 Selected: 1 Basket: 0 | Leidos | 8/16/2018 | $11,286,219 |
| RPP-18-01 (10/19/2017) | 18-02 (DET): Development of Multiplex Molecular Diagnostics Based on CRISPR-Cas and other Synthetic Biology Approaches | DTRA JSTO | Received: 0 Selected: Basket: | No Award Made | ||
| RPP-18-01 (10/19/2017) | 18-01 (DET): Rapid Single-molecule-based Diagnostic Platform Assessment of Pathogen Susceptibility to Anti-microbial Agent | DTRA JSTO | Received: 6 Selected: 2 Basket: 0 | California Institute of Technology General Electric | 12/4/2018 12/13/2018 | $3,387,096 $6,943,817 |
| RPP-17-03 (6/17/2017) | 17-08: Chemical Exposure In Vitro Diagnostics (ChemDx) | JPM CBRN Medical | Received: 3 Selected: 2 Basket: 1 | MRI Global | 10/10/2018 | $10,105,000 |
| RPP-17-03 (6/17/2017) | 17-07: Man-Portable Diagnostics System (MPDS) – Expanded Scope | JPM CBRN Medical | Received: 4 Selected: 1 Basket: 1 | Cepheid | 8/24/2018 | $86,564,949 |
| RPP-17-03 (6/17/2017) | 17-06: Execution of Phase 1 Clinical Study for Venezuelan Equine Encephalitis (VEE) Monovalent Virus Replicon Particle (VRP) vaccine | JPM CBRN Medical | Received: 4 Selected: 0 Basket: 2 | No Award Made at This Time | ||
| RPP-17-02 (2/13/2017) | 17-05: Man-Portable Diagnostics System (MPDS) | JPM CBRN Medical | Received: 3 Selected: 1 Basket: 1 | MRI Global | 9/1/2017 | $44,307,569 |
| RPP-17-02 (2/13/2017) | 17-04: Development of Multi-Target Single-Vector Vaccine Prototype against aerosolized Venezuelan Equine Encephalitis Virus (VEEV) | JPM CBRN Medical | Received: 1 Selected: 1 Basket: 0 | Bavarian Nordic | 3/16/2018 | $33,013,077 |
| RPP-17-02 (2/13/2017) | 17-03: Development of Marburgvirus (MARV) Vaccine Prototype against aerosolized MARV | JPM CBRN Medical | Received: 2 Selected: 1 Basket: 1 | Selectee did not execute Base Agreement | ||
| RPP-17-01 (1/13/2017) | 17-02: Development of Efficacious Antiviral Countermeasures | JPM CBRN Medical | Received: 5 Selected: 0 Basket: 2 | *Mapp BioPharmaceuticals | 11/7/2017 | $40,831,616 |
| RPP-17-01 (1/13/2017) | 17-01: Development of Monoclonal Antibody and Related Technologies as Medical Countermeasures against aerosolized Venezuelan Equine Encephalitis (VEE) Virus | JPM CBRN Medical | Received: 3 Selected: 0 Basket: 2 | No Award Made at This Time | ||
| RPP-16-02 (7/15/2016) | 16-06: Eastern Equine Encephalitis Virus Advanced Technology Demonstration (EEEV ATD) | JPM CBRN Medical | Received: 6 Selected: 0 Basket: 4 | No Award Made at This Time | ||
| RPP-16-02 (7/15/2016) | 16-05: Venezuelan equine encephalitis (VEE) Monovalent VLP Phase I Clinical Study | JPM CBRN Medical | Received: 2 Selected: 1 Basket: 1 | SRI International | 2/3/2017 | $5,054,959 |
| RPP-16-02 (7/15/2016) | 16-04: Lyophilized Formulation and Final Product Manufacturing Process for WEVEE Vaccine | JPM CBRN Medical | Received: 1 Selected: 0 Basket: 1 | No Award Made at This Time | ||
| RPP-16-02 (7/15/2016) | 16-03: Development of a Dual Drug Delivery Device (D4) Autoinjector | JPM CBRN Medical | Received: 5 Selected: 1 Basket: 2 | Emergent BioSolutions | 7/25/2017 | $28,513,274 |
| RPP-16-01 (6/22/2016) | 16-02: Development of Monoclonal Antibody Medical Countermeasures against Aerozolized Botulinum Toxin Serotypes A and B | JPM CBRN Medical | Received: 1 Selected: 1 Basket: 0 | Ology Bioservices | 9/30/2016 | $46,951,782 |
| RPP-16-01 (6/22/2016) | 16-01: Fill/Finish of Venezuelan Equine Encephalitis (VEE) virus like particle (VLP) Bulk Drug Product | JPM CBRN Medical | Received: 3 Selected: 1 Basket: 1 | SRI International | 12/8/2016 | $660,715 |